[Rilzabrutinib image courtesy of PubChem]
A Phase 1/2 study (NCT03395210) investigating Sanofi (Nasdaq:SNY) Bruton tyrosine kinase inhibitor rilzabrutinib in immune thrombocytopenia (ITP) has also shed light on the cognitive impairment involved in the disease.Patients with ITP, an autoimmune disease that involves increased platelet destruction, have often complained of fatigue, problems with cognition and other symptoms that physicians have dismissed, according to Dr. David Kuter, the director of clinical hematology at Massachusetts General Hospital, professor of medicine at Harvard Medical School, lead author of the NCT03395210 study. “What’s relevant about this study is that it is probably the first time that we’ve done real testing on patients to demonstrate there is a defect in ITP patients in terms of their cognition,” Kuter said.
The topic of cognitive impairment in ITP has …